Home/Pipeline/AI Model for Predicting Treatment-Related Interstitial Lung Disease

AI Model for Predicting Treatment-Related Interstitial Lung Disease

Oncology (complication of cancer treatment)

Research/ExploratoryActive

Key Facts

Indication
Oncology (complication of cancer treatment)
Phase
Research/Exploratory
Status
Active
Company

About Radiomics

Radiomics is a pioneering AI-driven clinical research organization (CRO) based in Leuven, Belgium, that transforms medical images into actionable data for oncology drug development. Its core offering combines a proprietary platform, Ikonics®, with advanced radiomics services to characterize disease, evaluate treatment response, and predict patient outcomes for clinical trial sponsors. The company partners with pharmaceutical firms like AstraZeneca and positions itself at the intersection of AI, medical imaging, and clinical research to enable data-driven decision-making in oncology trials.

View full company profile

Therapeutic Areas